Key result
Brequinar at a concentration of provided 25% protection for 5 days following FMDV challenge in a mouse model of infection.
Why the study?
The foot-and-mouth disease vaccine does not provide effective protection until adaptive immunity occurs, creating a need for antiviral agents to inhibit the virus.
Does brequinar prevent foot-and-mouth disease virus infection in vitro and in vivo?
Does brequinar prevent foot-and-mouth disease virus infection in vitro and in vivo?
Brequinar exhibits antiviral activity against foot-and-mouth disease virus in vitro and provides partial protection in a mouse model, suggesting potential as an antiviral agent.
Answers are grounded in this paper and cite their sources.
Brequinar shows anti-FMDV activity in swine cells; leaves open translation to in vivo efficacy or adjunct use in livestock.
Foot-and-mouth disease (FMD) is one of the most highly contagious animal disease that affects cloven-hoofed animals. However, the FMD vaccine does not provide effective protection until adaptive immune protection elicited by the vaccination occurs. Therefore, an alternative application of antiviral agents for inhibition of the FMD virus (FMDV) is needed. Here, we demonstrated that brequinar could exhibit antiviral activity in swine kidney cells (IBRS-2 cells) infected with two different FMDV serotypes. Subsequently, in vivo activity of brequinar was confirmed in a mouse model of infection. Specifically, brequinar at a concentration of 50 μg, provided 25% protection for 5 days following FMDV challenge. These results suggested that brequinar could be used as effective antiviral agent against FMD.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied Foot-and-mouth disease (FMD). Brequinar was evaluated on Protection following FMDV challenge. Brequinar at a concentration of provided 25% protection for 5 days following FMDV challenge in a mouse model of infection.
Synapse has enriched 10 related papers. Consider them for comparative context: